Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma

NCT07569068 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Gastric or Esophagogastric Junction Adenocarcinoma

Interventions

DRUG: Tislelizumab, LM-302 and S-1
DRUG: Tislelizumab combined with oxaliplatin and S-1

Sponsor

Ruijin Hospital